Covid19 Clinical Trial
Official title:
Timing of Corticosteroids in COVID-19, II. Post COVID-19 Follow-up
Verified date | September 2023 |
Source | ClinAmygate |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Timing of of corticosteroids administration is very important in COVID19 cases for the recovery and decrease the mortality.
Status | Active, not recruiting |
Enrollment | 752 |
Est. completion date | October 15, 2023 |
Est. primary completion date | November 1, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - any case with COVID-19 more than or equal to 18 years - mild and moderate severity Exclusion Criteria: - Severe to critical COVID-19 - Any contra-indication for the interventional drug - Mentally disabled cases |
Country | Name | City | State |
---|---|---|---|
Egypt | Asalam | Maadi | Cairo |
Lead Sponsor | Collaborator |
---|---|
ClinAmygate |
Egypt,
Spoorenberg SM, Deneer VH, Grutters JC, Pulles AE, Voorn GP, Rijkers GT, Bos WJ, van de Garde EM. Pharmacokinetics of oral vs. intravenous dexamethasone in patients hospitalized with community-acquired pneumonia. Br J Clin Pharmacol. 2014 Jul;78(1):78-83. doi: 10.1111/bcp.12295. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of cases that will need hospitalization | Deterioration in the clinical picture of cases that necessitate hospitalization | 10 days | |
Primary | Percentage of cases that will need oxygen supplementation | Percentage of cases whose clinical status deteriorate that their sPO2 become less than 92% | 10 days | |
Primary | 28-days mortality | Percentage of cases who died within 28 days of presentation | 28 days | |
Secondary | Percentages of COVID-19 Severity according to CDC 2020 | Percentages of COVID-19 severity according to CDC 2020 | 10 days | |
Secondary | Time to return to daily activity | Time to return to daily activity level | 60 days | |
Secondary | Percentage of cases with increased d-dimer | Percentage of cases with increased d-dimer from baseline | 10 days | |
Secondary | Percentage reduction in CRP | Percentage reduction in CRP from baseline | 10 days | |
Secondary | Percentage reduction in LDH | Percentage reduction in LDH from baseline | 10 days | |
Secondary | Percentage reduction in Ferritin | Percentage reduction in Ferritin from baseline | 10 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |